Veradigm Inc (MDRX)
OTCMKTS: MDRX · Delayed Price · USD
9.50
-0.16 (-1.66%)
Jul 5, 2024, 3:56 PM EDT - Market open
Veradigm Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
8,000
Market Cap
1.02B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 0 | - | - |
Dec 31, 2021 | 1.50B | 300.00K | 0.02% |
Dec 31, 2020 | 1.50B | -269.00M | -15.18% |
Dec 31, 2019 | 1.77B | 21.70M | 1.24% |
Dec 31, 2018 | 1.75B | -56.30M | -3.12% |
Dec 31, 2017 | 1.81B | 256.40M | 16.54% |
Dec 31, 2016 | 1.55B | 163.50M | 11.79% |
Dec 31, 2015 | 1.39B | 8.50M | 0.62% |
Dec 31, 2014 | 1.38B | 4.80M | 0.35% |
Dec 31, 2013 | 1.37B | -73.20M | -5.06% |
Dec 31, 2012 | 1.45B | -2.80M | -0.19% |
Dec 31, 2011 | 1.45B | 744.60M | 105.69% |
Dec 31, 2010 | 704.50M | 2.00K | 0.00% |
May 31, 2010 | 704.50M | 320.70M | 83.56% |
May 31, 2008 | 383.80M | 101.89M | 36.14% |
Dec 31, 2007 | 281.91M | 53.94M | 23.66% |
Dec 31, 2006 | 227.97M | 107.41M | 89.09% |
Dec 31, 2005 | 120.56M | 19.79M | 19.64% |
Dec 31, 2004 | 100.77M | 14.93M | 17.39% |
Dec 31, 2003 | 85.84M | 7.04M | 8.93% |
Dec 31, 2002 | 78.80M | 8.05M | 11.37% |
Dec 31, 2001 | 70.75M | 8.07M | 12.87% |
Dec 31, 2000 | 62.69M | 35.09M | 127.13% |
Dec 31, 1999 | 27.60M | 3.90M | 16.46% |
Dec 31, 1998 | 23.70M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 379.49B |
Johnson & Johnson | 81.80B |
Merck & Co. | 61.40B |
AbbVie | 54.40B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.49B |
Abbott Laboratories | 40.33B |
MDRX News
- 26 days ago - Black Book ranks Veradigm Payer Analytics the #1 Overall Payer Analytics Solutions Vendor in 2024 - Business Wire
- 27 days ago - The Portnoy Law Firm Announces Investigation of Veradigm Inc. (OTCMKTS: MDRX) - GlobeNewsWire
- 4 weeks ago - Robbins LLP Reminds MDRX Stockholders it is Investigating the Officers and Directors of Veradigm Inc. to Determine if They Breached Fiduciary Duties Owed to Shareholders - Business Wire
- 4 weeks ago - Robbins LLP Informs Investors it is Investigating the Officers and Directors of Veradigm Inc. (MDRX) for Breaches of Fiduciary Duty - GlobeNewsWire
- 5 weeks ago - Veradigm Payerpath Rated Highest in Client Satisfaction - Business Wire
- 5 weeks ago - Veradigm to Explore Strategic Alternatives and Reaffirms 2024 Guidance - Business Wire
- 5 weeks ago - Veradigm Announces Leadership Updates - Business Wire
- 7 weeks ago - Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Veradigm Inc. (MDRX) on Behalf of Investors - Business Wire